DE19531277A1
(de)
*
|
1995-08-25 |
1997-02-27 |
Basf Ag |
Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
|
DE19536387A1
(de)
*
|
1995-09-29 |
1997-04-03 |
Basf Ag |
Verfahren zur Herstellung von vitaminhaltigen festen Zubereitungen
|
CA2214895C
(en)
*
|
1997-09-19 |
1999-04-20 |
Bernard Charles Sherman |
Improved pharmaceutical composition comprising fenofibrate
|
TW568788B
(en)
*
|
1998-10-12 |
2004-01-01 |
Chugai Pharmaceutical Co Ltd |
Polymer combining with phosphoric acid and preparation containing the same
|
JP3572213B2
(ja)
*
|
1999-01-18 |
2004-09-29 |
信越化学工業株式会社 |
低置換度ヒドロキシプロピルセルロース
|
US6733789B1
(en)
|
1999-01-21 |
2004-05-11 |
Biovail Laboratories, Inc. |
Multiparticulate bisoprolol formulation
|
DE19916383A1
(de)
*
|
1999-03-31 |
2000-10-05 |
Schering Ag |
Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
|
JP2000327701A
(ja)
*
|
1999-05-18 |
2000-11-28 |
Shin Etsu Chem Co Ltd |
低置換度ヒドロキシプロピルセルロース及び固形製剤
|
US6555139B2
(en)
|
1999-06-28 |
2003-04-29 |
Wockhardt Europe Limited |
Preparation of micron-size pharmaceutical particles by microfluidization
|
DE19934610A1
(de)
*
|
1999-07-23 |
2001-01-25 |
Bayer Ag |
Schnellfreisetzende Extrudate und Verfahren zu ihrer Herstellung sowie daraus erhältliche Zubereitungen
|
BR0013488A
(pt)
|
1999-08-24 |
2002-05-07 |
Siemens Ag |
Equipamento de aspiração para um motor de combustão interna
|
SI1225874T1
(sl)
|
1999-09-24 |
2006-06-30 |
Janssen Pharmaceutica Nv |
Protivirusne trdne disperzije
|
WO2001034119A2
(en)
*
|
1999-11-12 |
2001-05-17 |
Abbott Laboratories |
Inhibitors of crystallization in a solid dispersion
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
US20040185099A1
(en)
*
|
2000-01-20 |
2004-09-23 |
Biovail Laboratories, Inc. |
Multiparticulate bisoprolol formulation
|
DE10026698A1
(de)
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
US20050175687A1
(en)
*
|
2001-01-30 |
2005-08-11 |
Mcallister Stephen M. |
Pharmaceutical formulations
|
US7842308B2
(en)
|
2001-01-30 |
2010-11-30 |
Smithkline Beecham Limited |
Pharmaceutical formulation
|
GB0102342D0
(en)
|
2001-01-30 |
2001-03-14 |
Smithkline Beecham Plc |
Pharmaceutical formulation
|
US7883721B2
(en)
|
2001-01-30 |
2011-02-08 |
Smithkline Beecham Limited |
Pharmaceutical formulation
|
US6555581B1
(en)
|
2001-02-15 |
2003-04-29 |
Jones Pharma, Inc. |
Levothyroxine compositions and methods
|
US20030224047A1
(en)
*
|
2001-02-15 |
2003-12-04 |
Franz G. Andrew |
Levothyroxine compositions and methods
|
US20030032675A1
(en)
*
|
2001-02-15 |
2003-02-13 |
Franz G. Andrew |
Manufacture of thyroid hormone tablets having consistent active moiety amounts
|
WO2002064093A2
(en)
*
|
2001-02-15 |
2002-08-22 |
King Pharmaceuticals, Inc. |
Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
|
JP2004534811A
(ja)
*
|
2001-06-22 |
2004-11-18 |
ファイザー・プロダクツ・インク |
ポリマーと薬剤の集合体を含む医薬組成物
|
EP1404300B1
(en)
*
|
2001-06-22 |
2009-09-30 |
Pfizer Products Inc. |
Pharmaceutical compositions of dispersions of drugs and neutral polymers
|
US20030198671A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique plasma AUC properties
|
US20030180353A1
(en)
*
|
2001-08-10 |
2003-09-25 |
Franz G. Andrew |
Stabilized pharmaceutical compositions
|
US20030198667A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz Andrew G. |
Methods of producing dispersible pharmaceutical compositions
|
US20030190349A1
(en)
*
|
2001-08-10 |
2003-10-09 |
Franz G. Andrew |
Methods of stabilizing pharmaceutical compositions
|
US20030203967A1
(en)
*
|
2001-08-14 |
2003-10-30 |
Franz G. Andrew |
Levothyroxine compositions having unique Tmax properties
|
US20030198672A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique triidothyronine plasma AUC properties
|
US20030199586A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Unique levothyroxine aqueous materials
|
US7101569B2
(en)
|
2001-08-14 |
2006-09-05 |
Franz G Andrew |
Methods of administering levothyroxine pharmaceutical compositions
|
US20030195253A1
(en)
*
|
2001-08-14 |
2003-10-16 |
Franz G. Andrew |
Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
|
US20030199587A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique Cmax properties
|
US20030180356A1
(en)
*
|
2001-10-29 |
2003-09-25 |
Franz G. Andrew |
Levothyroxine compositions having unique triiodothyronine Tmax properties
|
US7491407B2
(en)
*
|
2001-10-31 |
2009-02-17 |
North Carolina State University |
Fiber-based nano drug delivery systems (NDDS)
|
US20030118652A1
(en)
*
|
2001-11-15 |
2003-06-26 |
John Kelly |
Methods and compositions for use of (S)-bisoprolol
|
US20030091633A1
(en)
*
|
2001-11-15 |
2003-05-15 |
John Kelly |
Methods and compositions for use of (S)-bisoprolol
|
EP1920766B1
(en)
|
2002-02-01 |
2017-08-23 |
Bend Research, Inc |
Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
|
DE60322665D1
(de)
|
2002-02-01 |
2008-09-18 |
Pfizer Prod Inc |
Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
KR20040011248A
(ko)
*
|
2002-07-30 |
2004-02-05 |
환인제약 주식회사 |
암로디핀의 고체분산체와 그 제조방법 및 그를 포함하는약학적 조성물
|
ATE442130T1
(de)
|
2002-08-12 |
2009-09-15 |
Bend Res Inc |
Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren
|
DK1556021T3
(da)
|
2002-10-24 |
2008-04-28 |
Immupharm As |
Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
|
WO2004056358A1
(en)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
|
US7423004B2
(en)
*
|
2003-01-31 |
2008-09-09 |
Smithkline Beecham Corporation |
Solid dispersion compositions
|
TW200526274A
(en)
|
2003-07-21 |
2005-08-16 |
Smithkline Beecham Plc |
Pharmaceutical formulations
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
US8075872B2
(en)
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
DE102004032051A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
US8377952B2
(en)
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
US8025899B2
(en)
*
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
EP1696887A1
(en)
*
|
2003-11-14 |
2006-09-06 |
Pfizer Products Inc. |
Solid amorphous dispersions of an mtp inhibitor for treatment of obesity
|
BRPI0417492A
(pt)
*
|
2003-12-09 |
2007-05-29 |
Pfizer |
composições compreendendo um inibidor de protease de hiv
|
AU2005214159A1
(en)
|
2004-02-04 |
2005-09-01 |
Pfizer Products Inc. |
Substituted quinoline compounds
|
TW201240679A
(en)
|
2004-03-12 |
2012-10-16 |
Capsugel Belgium Nv |
Pharmaceutical formulations
|
GEP20094723B
(en)
|
2004-05-25 |
2009-07-10 |
Pfizer Prod Inc |
Tetraazabenzo [e] azulene derivatives and analogs thereof
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
ATE526949T1
(de)
*
|
2004-08-12 |
2011-10-15 |
Reckitt Benckiser Healthcare |
Durch schmelzextrusion hergestelltes granulat mit einem nichtsteroidalen antiinflammatorischen wirkstoff und einem zuckeralkohol
|
EP1941798B1
(en)
|
2004-12-17 |
2012-05-23 |
Devgen NV |
Nematicidal compositions
|
EP2548894A1
(en)
|
2005-02-03 |
2013-01-23 |
Bend Research, Inc. |
Pharmaceutical compositions with enhanced performance
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
NZ585116A
(en)
*
|
2005-05-10 |
2011-12-22 |
Novartis Ag |
Extrusion process for making compositions with poorly compressible therapeutic compounds e.g. metformin hydrochloride
|
NZ572207A
(en)
|
2006-03-24 |
2012-02-24 |
Auxilium Int Holdings Inc |
Stabilized compositions containing alkaline labile drugs
|
WO2007112285A2
(en)
*
|
2006-03-24 |
2007-10-04 |
Auxilium Pharmaceuticals, Inc. |
Process for the preparation of a hot-melt extruded laminate
|
CN101460149A
(zh)
*
|
2006-06-07 |
2009-06-17 |
巴斯夫欧洲公司 |
醋酸乙烯酯-磺酸盐共聚物作为微水溶性化合物的加溶剂的用途
|
US8343547B2
(en)
*
|
2006-08-08 |
2013-01-01 |
Shin-Etsu Chemical Co., Ltd. |
Solid dosage form comprising solid dispersion
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
US20080187579A1
(en)
*
|
2007-02-01 |
2008-08-07 |
Pavan Bhat |
Extended-release dosage form
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
AU2008274352B2
(en)
*
|
2007-07-06 |
2014-01-16 |
Basf Se |
Use of homo- and copolymers for stabilizing active ingredient formulations
|
US8183381B2
(en)
*
|
2007-07-19 |
2012-05-22 |
Metabolex Inc. |
N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
|
JP2011503048A
(ja)
|
2007-11-08 |
2011-01-27 |
グラクソ グループ リミテッド |
医薬製剤
|
WO2009085637A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Url Pharma, Inc. |
Amorphous metaxalone and amorphous dispersions thereof
|
KR101616246B1
(ko)
|
2008-01-25 |
2016-05-02 |
그뤼넨탈 게엠베하 |
약제학적 투여형
|
MX2010010562A
(es)
*
|
2008-03-31 |
2010-12-07 |
Metabolex Inc |
Compuestos de oximetilen-arilo y uso de los mismos.
|
MX2010012039A
(es)
|
2008-05-09 |
2010-11-30 |
Gruenenthal Gmbh |
Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
|
TW201010745A
(en)
*
|
2008-06-13 |
2010-03-16 |
Glaxo Group Ltd |
Pharmaceutical formulations
|
PT2309987E
(pt)
*
|
2008-07-03 |
2012-12-13 |
Novartis Ag |
Processo para granulação por fusão
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
HUE048542T2
(hu)
|
2009-06-16 |
2020-08-28 |
Pfizer |
Apixaban adagolási formái
|
MX2012000317A
(es)
|
2009-07-22 |
2012-02-08 |
Gruenenthal Gmbh |
Forma de dosificacion de liberacion controlada extruida por fusion en caliente.
|
RU2015138422A
(ru)
|
2009-07-22 |
2018-12-25 |
Грюненталь Гмбх |
Стабильная при окислении, прочная на излом лекарственная форма
|
ES2497566T3
(es)
*
|
2009-10-01 |
2014-09-23 |
Cymabay Therapeutics, Inc. |
Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
|
EP2571860A1
(en)
|
2010-05-21 |
2013-03-27 |
Pfizer Inc |
2-phenyl benzoylamides
|
EP2585048B1
(en)
|
2010-06-23 |
2018-04-11 |
CymaBay Therapeutics, Inc. |
Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
ES2487244T3
(es)
|
2010-09-02 |
2014-08-20 |
Grünenthal GmbH |
Forma de dosificación resistente a la manipulación que comprende un polímero aniónico
|
CA2808219C
(en)
|
2010-09-02 |
2019-05-14 |
Gruenenthal Gmbh |
Tamper resistant dosage form comprising inorganic salt
|
EP2654731B1
(en)
|
2010-12-23 |
2016-07-27 |
AbbVie Deutschland GmbH & Co. KG |
Solid retard formulations based on solid dispersions
|
CA2824639A1
(en)
|
2011-02-17 |
2012-08-23 |
Ashish Chatterji |
A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
|
BR112013023879B1
(pt)
*
|
2011-03-21 |
2022-08-30 |
Boehringer Ingelheim International Gmbh |
Preparações sólidas que contém ambroxol, seu método de preparação, forma de dosagem farmacêutica e seus usos
|
AU2012292418B2
(en)
|
2011-07-29 |
2017-02-16 |
Grunenthal Gmbh |
Tamper-resistant tablet providing immediate drug release
|
CA2839123A1
(en)
|
2011-07-29 |
2013-02-07 |
Grunenthal Gmbh |
Tamper-resistant tablet providing immediate drug release
|
MX356421B
(es)
|
2012-02-28 |
2018-05-29 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
|
CN104334557A
(zh)
|
2012-04-06 |
2015-02-04 |
辉瑞公司 |
二酰基甘油酰基转移酶2抑制剂
|
CN104394851B
(zh)
|
2012-04-18 |
2017-12-01 |
格吕伦塔尔有限公司 |
抗篡改和抗剂量‑倾泻药物剂型
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
EP2925880B1
(en)
*
|
2012-11-27 |
2020-07-01 |
DSM IP Assets B.V. |
Process for the production of discrete solid extruded particles
|
AR096438A1
(es)
|
2013-05-29 |
2015-12-30 |
Gruenenthal Gmbh |
Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
|
CA2907950A1
(en)
|
2013-05-29 |
2014-12-04 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing one or more particles
|
US10646573B2
(en)
*
|
2013-06-03 |
2020-05-12 |
Shin-Etsu Chemical Co., Ltd. |
Composition for hot melt extrusion and method for producing hot melt extrudate by using same
|
BR112016000194A8
(pt)
|
2013-07-12 |
2019-12-31 |
Gruenenthal Gmbh |
forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
|
US10022337B2
(en)
|
2013-11-15 |
2018-07-17 |
Dsm Ip Assets B.V. |
Formulation of sparingly soluble compounds by hot-melt extrusion
|
CN105934241B
(zh)
|
2013-11-26 |
2020-06-05 |
格吕伦塔尔有限公司 |
通过低温研磨制备粉末状药物组合物
|
EP3119757B1
(en)
|
2014-03-17 |
2018-05-16 |
Pfizer Inc |
Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
|
WO2015173195A1
(en)
|
2014-05-12 |
2015-11-19 |
Grünenthal GmbH |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
JP2017516789A
(ja)
|
2014-05-26 |
2017-06-22 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
エタノール過量放出に対して防護されている多粒子
|
EP3285745A1
(en)
|
2015-04-24 |
2018-02-28 |
Grünenthal GmbH |
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
CA2998259A1
(en)
|
2015-09-10 |
2017-03-16 |
Grunenthal Gmbh |
Protecting oral overdose with abuse deterrent immediate release formulations
|
CN108135849A
(zh)
|
2015-10-07 |
2018-06-08 |
帝斯曼知识产权资产管理有限公司 |
多维生素挤出物
|
KR20190035752A
(ko)
|
2016-08-03 |
2019-04-03 |
사이머베이 쎄라퓨틱스, 인코퍼레이티드 |
염증성 위장 질환 또는 위장 상태를 치료하기 위한 옥시메틸렌 아릴 화합물
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
WO2018115130A1
(en)
|
2016-12-23 |
2018-06-28 |
Hermes Arzneimittel Gmbh |
Oral pharmaceutical composition with improved taste-masking properties
|
US11312713B2
(en)
|
2017-03-10 |
2022-04-26 |
Pfizer Inc. |
Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors
|
TWI718644B
(zh)
|
2018-08-31 |
2021-02-11 |
美商輝瑞股份有限公司 |
用於治療nash/nafld和相關疾病之組合
|
CN114007697A
(zh)
|
2019-04-19 |
2022-02-01 |
辉瑞公司 |
用于治疗pah的抗增殖剂
|
CN113874019A
(zh)
|
2019-05-20 |
2021-12-31 |
辉瑞大药厂 |
用于治疗nash/nafld及相关疾病的包含作为glp-1r激动剂的苯并二氧杂环戊烯的组合
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
CA3144848C
(en)
|
2019-06-28 |
2023-11-21 |
Pfizer Inc. |
5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
JP2021134211A
(ja)
|
2020-02-24 |
2021-09-13 |
ファイザー・インク |
Nafld/nashおよび関連疾患の処置のための組合せ
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
EP4161927A1
(en)
|
2020-06-09 |
2023-04-12 |
Pfizer Inc. |
Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
|
WO2023100061A1
(en)
|
2021-12-01 |
2023-06-08 |
Pfizer Inc. |
3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
|
WO2023105387A1
(en)
|
2021-12-06 |
2023-06-15 |
Pfizer Inc. |
Melanocortin 4 receptor antagonists and uses thereof
|
WO2024075051A1
(en)
|
2022-10-07 |
2024-04-11 |
Pfizer Inc. |
Hsd17b13 inhibitors and/or degraders
|